Filing Flows › 60 Degrees Pharmaceuticals (SXTP) › Q4 2025
60 Degrees Pharmaceuticals (SXTP) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 30, 2026
60 Degrees Pharmaceuticals (SXTP) reported revenue of $303K for the fourth quarter 2025 (Q4 2025), +26% from a year earlier and -31% from the quarter before. Operating margin was -632.0%, net loss $1.4M (474.3% of revenue).
60 Degrees Pharmaceuticals, Q4 2025: revenue $303K (+26% year over year), operating margin -632.0%, net loss $1.4M, operating cash flow −$1.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $303K | -31% | +26% |
| Operating profit | −$1.9M | — | — |
| Net earnings | −$1.4M | — | — |
| Operating cash flow | −$1.7M | — | — |
What changed
Revenue was $303K in Q4 2025, up 26% year over year and down 31% from the previous quarter.
Gross margin was 60.2%, up 9.1 points from Q4 2024. Operating costs exceeded revenue by $1.9M, an operating margin of -632.0%. Operating expenses fell 4% while revenue rose 26%. The quarter ended with a net loss of $1.4M, narrower than the previous quarter's $2.3M loss. Minority interests bore $0K of it: to shareholders the quarter was a loss of $1.4M. Non-operating items added $476K, -33% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$1.7M. Non-cash charges added back $24K of depreciation and amortization and $112K of share-based compensation. Working capital and other items used $389K. Capital expenditures of $80K exceeded it, leaving free cash flow of −$1.8M.
Questions
What was 60 Degrees Pharmaceuticals' revenue in the fourth quarter 2025?
60 Degrees Pharmaceuticals (SXTP) reported revenue of $303K for the fourth quarter 2025 (Q4 2025), +26% from a year earlier and -31% from the quarter before.
Was 60 Degrees Pharmaceuticals profitable in the fourth quarter 2025?
Operating loss was $1.9M (-632.0% of revenue) and net loss $1.4M.